238 related articles for article (PubMed ID: 32259703)
1. Hypoxia-activated nanomedicines for effective cancer therapy.
Zhou M; Xie Y; Xu S; Xin J; Wang J; Han T; Ting R; Zhang J; An F
Eur J Med Chem; 2020 Jun; 195():112274. PubMed ID: 32259703
[TBL] [Abstract][Full Text] [Related]
2. Modulating tumor hypoxia by nanomedicine for effective cancer therapy.
Jahanban-Esfahlan R; de la Guardia M; Ahmadi D; Yousefi B
J Cell Physiol; 2018 Mar; 233(3):2019-2031. PubMed ID: 28198007
[TBL] [Abstract][Full Text] [Related]
3. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-active nanoparticles used in tumor theranostic.
Wang Y; Shang W; Niu M; Tian J; Xu K
Int J Nanomedicine; 2019; 14():3705-3722. PubMed ID: 31190820
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives.
Thambi T; Park JH; Lee DS
Chem Commun (Camb); 2016 Jun; 52(55):8492-500. PubMed ID: 27225824
[TBL] [Abstract][Full Text] [Related]
6. Research progress on tumor hypoxia-associative nanomedicine.
Xu XX; Chen SY; Yi NB; Li X; Chen SL; Lei Z; Cheng DB; Sun T
J Control Release; 2022 Oct; 350():829-840. PubMed ID: 36100192
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated Prodrug Enabling Synchronous Chemotherapy and HIF-1α Downregulation for Tumor Treatment.
Luo X; Li A; Chi X; Lin Y; Liu X; Zhang L; Su X; Yin Z; Lin H; Gao J
Bioconjug Chem; 2021 May; 32(5):983-990. PubMed ID: 33847488
[TBL] [Abstract][Full Text] [Related]
8. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
9. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.
Baran N; Konopleva M
Clin Cancer Res; 2017 May; 23(10):2382-2390. PubMed ID: 28137923
[TBL] [Abstract][Full Text] [Related]
11. Advanced nanotechnology for hypoxia-associated antitumor therapy.
Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
[TBL] [Abstract][Full Text] [Related]
12. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
[TBL] [Abstract][Full Text] [Related]
13. Stimuli-responsive prodrug-based cancer nanomedicine.
Xie A; Hanif S; Ouyang J; Tang Z; Kong N; Kim NY; Qi B; Patel D; Shi B; Tao W
EBioMedicine; 2020 Jun; 56():102821. PubMed ID: 32505922
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Theranostic Liposomes Loaded with a Hypoxia-Activated Prodrug for Cascade-Activated Tumor Selective Combination Therapy.
Dai Y; Wang B; Sun Z; Cheng J; Zhao H; Wu K; Sun P; Shen Q; Li M; Fan Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39410-39423. PubMed ID: 31578854
[TBL] [Abstract][Full Text] [Related]
15. Strategies of Alleviating Tumor Hypoxia and Enhancing Tumor Therapeutic Effect by Macromolecular Nanomaterials.
Jin Z; Zhao Q; Yuan S; Jiang W; Hu Y
Macromol Biosci; 2021 Aug; 21(8):e2100092. PubMed ID: 34008312
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance.
Liu Y; Dong W; Ma Y; Dou J; Jiang W; Wang L; Wang Q; Li S; Wang Y; Li M
Biomaterials; 2023 Mar; 294():122023. PubMed ID: 36708621
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Nanomedicine Fabricated from Photosensitizer-Terminated Metal-Organic Framework Nanoparticles for Photodynamic Therapy and Hypoxia-Activated Cascade Chemotherapy.
He Z; Dai Y; Li X; Guo D; Liu Y; Huang X; Jiang J; Wang S; Zhu G; Zhang F; Lin L; Zhu JJ; Yu G; Chen X
Small; 2019 Jan; 15(4):e1804131. PubMed ID: 30565431
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment.
Pan Y; Liu L; Mou X; Cai Y
ACS Nano; 2023 Nov; 17(21):20875-20924. PubMed ID: 37871328
[TBL] [Abstract][Full Text] [Related]
19. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.
Graham K; Unger E
Int J Nanomedicine; 2018; 13():6049-6058. PubMed ID: 30323592
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumors with hypoxia-activated cytotoxins.
Ahn GO; Brown M
Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
